James B. Tananbaum
CIK 1581754 · President and CEO · last filed 2026-08-10
James B. Tananbaum is a President and CEO who has filed 30 SEC Form 4 insider transactions across 11 companies since 2013. The most recent filing, for LTGO, was dated Aug 10, 2026. Across all open-market trades the lifetime net is −$690.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $289.6M across reported positions. 29 SEC filings were submitted jointly with Foresite Capital Fund II, L.P.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TXG price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE PH1
WEST HOLLYWOOD, CA 90069
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) Delisted | Director | 3,562,984 | $15.26 | $54.37M | $2.52M | 1 | 2026-08-10 |
| ALMS | Director | 4,247,670 | $6.51 | $27.65M | $50.83M | 6 | 2026-04-03 |
| PARDES BIOSCIENCES, INC. (PRDS) Delisted | President and CEO | 1,000 | $2.16 | $2.2K | $3.48M | 5 | 2023-08-31 |
| Theseus Pharmaceuticals, Inc. (THRX) Delisted | 10%+ Owner | 4,108,796 | $4.06 | $16.68M | $10.39M | 1 | 2023-07-19 |
| Kinnate Biopharma Inc. (KNTE) Delisted | Director | 3,525,957 | $2.65 | $9.34M | $24.98M | 6 | 2023-05-10 |
| Disc Medicine, Inc. (GMTX) Delisted | Director | 150,000 | $13.50 | $2.02M | $0 | 2 | 2021-10-06 |
| QSI | Director | 4,484,131 | $1.46 | $6.55M | $0 | 1 | 2021-06-14 |
| Disc Medicine, Inc. (FSDC) Delisted | President & CEO | 441,500 | — | — | $17.66M | 1 | 2020-10-19 |
| TXG | 10%+ Owner | 3,500,000 | $72.96 | $255.36M | -$802.19M | 4 | 2020-05-14 |
| AERIE PHARMACEUTICALS INC (AERI) Delisted | 10%+ Owner | 1,672,714 | $15.25 | $25.51M | $0 | 1 | 2019-11-18 |
| AMBIT BIOSCIENCES CORP (AMBI) Delisted | 10%+ Owner | 2,036,616 | $0.54 | $1.10M | $1.65M | 1 | 2013-10-16 |
Recent Filings
30 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-10 | Latigo Biotherapeutics, Inc. (LTGO) Delisted | Mixed | +9,181,328 | $2.52M | EDGAR |
| 2026-04-03 | ALMS | Other (J) | −495,984 | $0 | EDGAR |
| 2026-01-12 | ALMS | Buy (P) | +411,764 | $7.00M | EDGAR |
| 2025-11-25 | ALMS | Buy (P) | +72,212 | $532.9K | EDGAR |
| 2025-11-19 | ALMS | Buy (P) | +507,874 | $3.09M | EDGAR |
| 2025-05-06 | ALMS | Buy (P) | +45,000 | $202.3K | EDGAR |
| 2024-07-03 | ALMS | Mixed | +13,976,484 | $40.00M | EDGAR |
| 2024-04-05 | — | Disp (D) | −13,718,311 | $0 | |
| 2023-08-31 | PARDES BIOSCIENCES, INC. (PRDS) Delisted | Mixed | −100,872,876 | $0 | EDGAR |
| 2023-07-19 | Theseus Pharmaceuticals, Inc. (THRX) Delisted | Buy (P) | +3,500,000 | $10.39M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.